Report
2011년 10월 11일
Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?
In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto…
Report
2011년 9월 28일
Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies – Abstract
The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater…
